Last updated: February 20, 2026
Who Are the Main Suppliers of VISIPAQUE 320?
VISIPAQUE 320, a contrast agent used in computed tomography (CT) imaging, is primarily supplied by GE Healthcare. Several regional distributors and authorized partners facilitate its distribution globally. The drug's manufacturing rights are held by GE Healthcare, with specific licensing agreements in various countries.
Primary Manufacturer and Supplier:
-
GE Healthcare
-
Location: Chicago, Illinois, USA
-
Product focus: Diagnostic imaging agents, including VISIPAQUE 320
Authorized Distributors & Regional Suppliers:
| Region |
Major Distributors |
Notes |
| North America |
GE Healthcare (direct supply) |
Direct sales through GE, with authorized regional distributors in the US, Canada |
| Europe |
GE Healthcare partners in Germany, UK, France |
Distribution through licensed regional partners |
| Asia-Pacific |
Local authorized distributors in China, Japan, India |
Often through regional subsidiaries of GE Healthcare |
| Latin America |
Local authorized distributors |
Licensed regional distribution networks |
| Middle East & Africa |
Regional distributors approved by GE |
Distribution agreements vary per country |
How Does the Supply Chain Function?
The supply chain for VISIPAQUE 320 involves several stages:
-
Manufacturing: GE Healthcare produces the drug at its facilities, ensuring compliance with Good Manufacturing Practice (GMP).
-
Distribution: The product is shipped to licensed regional distributors or directly to hospitals and clinics, depending on country regulations.
-
Regulatory Compliance: Suppliers must adhere to the specific medical device and drug regulations within each country, including approvals from agencies such as the FDA (U.S.) or EMA (Europe).
-
Supply Security: Given high global demand, GE Healthcare maintains multiple manufacturing lines and strategic stockpiles to prevent shortages.
Key Market Dynamics
-
Patent Status: No patent protections prevent generic entry; however, as of 2023, no generic equivalents exist forVISIPAQUE 320, given the licensing and regulatory hurdles.
-
Manufacturing Capacity: GE Healthcare has expanded production facilities in North America and Europe, with ongoing investments to meet global demand.
-
Price and Access: Cost varies regionally, influenced by purchasing agreements, insurance coverage, and local regulation.
Competitive Landscape
Currently, GE Healthcare is the sole supplier of VISIPAQUE 320. No authorized generic versions are available. Competition from other contrast agents exists but generally targets different imaging modalities or contrast levels.
Regulatory Approvals and Market Access
-
Approved by the FDA in 2004
-
Approved by the EMA in 2004
-
Marketed in over 70 countries
-
Subject to ongoing post-marketing surveillance and compliance checks
Summary of Supplier Footprint
-
GE Healthcare holds exclusive manufacturing rights
-
Distribution handled via regional authorized partners
-
Global availability depends on regulatory approvals, with a focus on markets in North America, Europe, and Asia-Pacific
Critical Product and Supply Info
| Attribute |
Details |
| Typical Pack Size |
50 mL, 100 mL vials |
| Storage Requirements |
Stored at 20-25°C, away from light |
| Shelf Life |
Typically up to 36 months |
| Pricing (approximate) |
Varies by region; $50-$200 per vial depending on purchase volume |
Conclusion
GE Healthcare is the exclusive manufacturer and primary supplier of VISIPAQUE 320. Distribution channels are regionally managed by authorized partners and distributors, with supply chains regulated according to local requirements. No generics are presently authorized, maintaining GE Healthcare’s market dominance.
Key Takeaways
-
GE Healthcare is the sole producer and primary supplier of VISIPAQUE 320.
-
Distribution involves regional licensed partners, with direct supply in major markets.
-
The product is approved globally, with no generic equivalents available as of 2023.
-
Manufacturing capacity expansion has supported stable supply, though regional shortages may occur.
-
Pricing varies regionally, influenced by local regulatory and procurement policies.
FAQs
Q1: Are there any generic versions of VISIPAQUE 320?
No. As of 2023, no generic alternatives are authorized due to patent and regulatory barriers.
Q2: How can I identify authorized suppliers in my country?
Consult GE Healthcare's regional offices or authorized distributors listed on their official website.
Q3: What are the storage requirements for VISIPAQUE 320?
Store at 20-25°C in a light-protected environment; avoid freezing or rapid temperature changes.
Q4: How does the supply chain ensure uninterrupted availability?
GE Healthcare maintains multiple manufacturing sites and regional inventories to meet global demand.
Q5: Is the supply affected by regulatory delays?
Regulatory approvals in new markets or renewals can influence supply; however, current supply chains are stable.
References
- GE Healthcare. (2022). VISIPAQUE (iodixanol) Summary of Product Characteristics.
- U.S. Food and Drug Administration. (2004). FDA Approval Letter for VISIPAQUE.
- European Medicines Agency. (2004). Marketing Authorization for VISIPAQUE.
- Global Market Insights. (2022). Diagnostic Imaging Market Report.
- WHO. (2021). International Medical Products Supply Chain Regulations.
